<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Methoxetamine - Complete Profile</title>
    <link rel="stylesheet" href="/style.css">
</head>

<body>
  <body class="
  
  
  
  ">
    <header class="page-header">
  <div class="container">
    <div class="page-header__content">
      <div class="logo-container">
        <a href="/" class="site-title">Dyo's Domain</a>
      </div>
      
      <nav>
        <ul role="list" class="nav-list flex-group">
          <li>
            <a href="/">Home</a>
          </li>
          <li>
            <a href="/dyos-domain/">Dyo's Domain</a>
          </li>
          <li>
            <a href="/about/">About</a>
          </li>
          <li>
            <a href="/profile/">My Profile</a>
          </li>
         
        </ul>
      </nav>
    </div>
    
    <!-- Search Bar - Now underneath header -->
    <div class="search-container">
      <input type="text" id="search-input" placeholder="Search substances..." class="search-input" />
      <div id="search-results" class="search-results" style="display: none;"></div>
    </div>
  </div>
</header>

    <main>
      
<div class="substance-profile-header">
  <div class="container">
    <nav class="breadcrumb">
      <a href="/dyos-domain/">Dyo's Domain</a> ‚Üí <a href="/dyos-domain/dissociatives/">Dissociatives</a> ‚Üí <span>Methoxetamine</span>
    </nav>
    
    <div class="substance-hero">
      <div class="substance-info">
        <h1>üåÄ Methoxetamine</h1>
        <h2 class="chemical-name">2-(Ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one</h2>
          <!-- Add to Profile Button -->
        <button id="add-to-profile-btn" class="add-to-profile-btn not-in-profile" 
                data-substance="Methoxetamine" 
                data-category="Dissociatives" 
                data-chemical="2-(Ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one">
          + Add to My Profile
        </button>
        
        <div class="alternative-names">
          <h3>Alternative Names & Slang</h3>
          <div class="names-grid">
            <div class="name-category">
              <h4>Common Names</h4>
              <span>MXE</span> ‚Ä¢ <span>Mexxy</span> ‚Ä¢ <span>M-Ket</span> ‚Ä¢ <span>Roflcoptr</span>
            </div>
            <div class="name-category">
              <h4>Research Chemical Names</h4>
              <span>3-MeO-2-Oxo-PCE</span> ‚Ä¢ <span>Methoxetamine HCl</span> ‚Ä¢ <span>MXE Crystal</span>
            </div>
            <div class="name-category">
              <h4>Street Names</h4>
              <span>Legal Ketamine</span> ‚Ä¢ <span>Special M</span> ‚Ä¢ <span>Kmax</span> ‚Ä¢ <span>Jetamine</span>
            </div>
            <div class="name-category">
              <h4>Chemical Abbreviations</h4>
              <span>MXE-HCl</span> ‚Ä¢ <span>3-MeO-2'-Oxo-PCE</span> ‚Ä¢ <span>N-Ethyl-3-MeO-PCE</span>
            </div>
          </div>
        </div>
        
        <div class="substance-meta-large">
          <span class="category research">Research Chemical</span>
          <span class="legal-status schedule-1">Schedule I</span>
          <span class="duration long">4-8 hours</span>
        </div>
      </div>
      
      <div class="substance-visual">
        <div class="substance-image">
          <img src="/assets/substances/methoxetamine.jpg" alt="MXE crystals and molecular structure diagram" class="substance-photo">
        </div>
        <div class="molecule-structure">
          <div class="structure-placeholder">
            <p>üß¨ C‚ÇÅ‚ÇÖH‚ÇÇ‚ÇÅNO‚ÇÇ</p>
            <p>MW: 247.33 g/mol</p>
          </div>
        </div>
      </div>
    </div>
  </div>
</div>

<div class="container">
  
  <div class="profile-grid">
    
    <div class="profile-section identification">
      <h3>üîç Physical Identification</h3>
      <div class="identification-info">
        <div class="pure-form">
          <h4>Pure Methoxetamine (HCl salt)</h4>
          <ul>
            <li><strong>Appearance:</strong> White to off-white crystalline powder</li>
            <li><strong>Texture:</strong> Fine powder, sometimes with small crystals</li>
            <li><strong>Odor:</strong> Generally odorless or faint chemical smell</li>
            <li><strong>Taste:</strong> Bitter, numbing, metallic aftertaste</li>
            <li><strong>Solubility:</strong> Soluble in water, highly soluble in alcohol</li>
          </ul>
        </div>
        
        <div class="street-forms">
          <h4>Research Chemical Forms (Historical)</h4>
          <ul>
            <li><strong>Powder:</strong> Most common form, white to slightly off-white</li>
            <li><strong>Crystals:</strong> Larger crystalline chunks, higher purity</li>
            <li><strong>Capsules:</strong> Pre-measured doses in gelatin capsules</li>
            <li><strong>Solution:</strong> Dissolved in saline for intramuscular injection</li>
          </ul>
        </div>
        
        <div class="adulterants-warning">
          <h4>‚ö†Ô∏è Modern Contamination Risks</h4>
          <p><strong>Current market:</strong> True MXE extremely rare since 2015 ban</p>
          <p><strong>Substitutes:</strong> 3-MeO-PCE, 3-HO-PCE, DCK, other dissociatives</p>
          <p><strong>Dangerous:</strong> Fentanyl contamination possible in any powder</p>
        </div>
      </div>
    </div>
    
    <div class="profile-section dosage">
      <h3>üíä Historical Dosage Information</h3>
      <div class="dosage-warning">
        <p><strong>‚ö†Ô∏è CRITICAL WARNING:</strong> Methoxetamine is extremely potent and has a steep dose-response curve. Small increases in dose can cause dramatic increases in effects, including dangerous dissociative states.</p>
      </div>
      
      <div class="dosage-routes">
        <h4>Oral Administration</h4>
        <div class="dosage-chart">
          <div class="dose-range threshold">
            <span class="range-label">Threshold</span>
            <span class="dose-amount">5-15mg</span>
            <div class="dose-bar"></div>
          </div>
          <div class="dose-range light">
            <span class="range-label">Light</span>
            <span class="dose-amount">15-25mg</span>
            <div class="dose-bar"></div>
          </div>
          <div class="dose-range common">
            <span class="range-label">Common</span>
            <span class="dose-amount">25-40mg</span>
            <div class="dose-bar"></div>
          </div>
          <div class="dose-range strong">
            <span class="range-label">Strong</span>
            <span class="dose-amount">40-60mg</span>
            <div class="dose-bar"></div>
          </div>
          <div class="dose-range heavy">
            <span class="range-label">M-Hole Risk</span>
            <span class="dose-amount">60mg+</span>
            <div class="dose-bar dangerous"></div>
          </div>
        </div>
        
        <h4>Insufflated (Nasal)</h4>
        <div class="dosage-chart">
          <div class="dose-range threshold">
            <span class="range-label">Threshold</span>
            <span class="dose-amount">3-8mg</span>
            <div class="dose-bar"></div>
          </div>
          <div class="dose-range light">
            <span class="range-label">Light</span>
            <span class="dose-amount">8-15mg</span>
            <div class="dose-bar"></div>
          </div>
          <div class="dose-range common">
            <span class="range-label">Common</span>
            <span class="dose-amount">15-25mg</span>
            <div class="dose-bar"></div>
          </div>
          <div class="dose-range strong">
            <span class="range-label">Strong</span>
            <span class="dose-amount">25-40mg</span>
            <div class="dose-bar"></div>
          </div>
          <div class="dose-range heavy">
            <span class="range-label">M-Hole Risk</span>
            <span class="dose-amount">40mg+</span>
            <div class="dose-bar dangerous"></div>
          </div>
        </div>
      </div>
      
      <div class="dosage-details">
        <h4>Critical Dosage Considerations</h4>
        <ul>
          <li><strong>Steep dose curve:</strong> Small increases cause dramatic effect changes</li>
          <li><strong>Long duration:</strong> 4-8 hours makes redosing extremely dangerous</li>
          <li><strong>Delayed onset:</strong> Can take 1-2 hours orally - resist redosing urge</li>
          <li><strong>Individual variation:</strong> Some users extremely sensitive</li>
          <li><strong>Tolerance:</strong> Develops rapidly with repeated use</li>
        </ul>
      </div>
      
      <p class="dosage-note"><strong>Fatal Warning:</strong> The "M-hole" (complete dissociative anesthesia) can occur with surprisingly low doses in some individuals. This state carries significant risks of injury, aspiration, and death.</p>
    </div>

    <div class="profile-section effects">
      <h3>‚ú® Effects Profile</h3>
      
      <div class="effects-timeline">
        <h4>Timeline (Oral)</h4>
        <div class="timeline-item">
          <span class="time">T+0:15-1:30</span>
          <span class="effect">Onset - mild dissociation, mood lift</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+1:30-4:00</span>
          <span class="effect">Peak - strong dissociation, potential M-hole</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+4:00-8:00</span>
          <span class="effect">Plateau - continued dissociation, gradual descent</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+8:00-24:00</span>
          <span class="effect">Afterglow - lingering effects, mood changes</span>
        </div>
      </div>

      <div class="effects-categories">
        <div class="effect-category positive">
          <h4>‚úÖ Reported Positive Effects</h4>
          <ul>
            <li>Euphoria and mood elevation</li>
            <li>Dissociative experiences and ego dissolution</li>
            <li>Enhanced music appreciation</li>
            <li>Introspective and philosophical thoughts</li>
            <li>Pain relief and analgesia</li>
            <li>Unique "warm" dissociation vs. ketamine</li>
          </ul>
        </div>
        
        <div class="effect-category negative">
          <h4>‚ùå Dangerous Side Effects</h4>
          <ul>
            <li>Complete loss of motor control</li>
            <li>Memory blackouts and amnesia</li>
            <li>Dangerous confusion and disorientation</li>
            <li>Potential for injury while dissociated</li>
            <li>Nausea and vomiting</li>
            <li>Psychological dependence</li>
            <li>Potential mania induction</li>
          </ul>
        </div>
      </div>
      
      <div class="mhole-warning">
        <h4>üï≥Ô∏è The M-Hole Experience</h4>
        <p>At higher doses, MXE can induce a complete dissociative state called the "M-hole" - similar to ketamine's K-hole but longer lasting. Users report complete separation from their body, inability to move or communicate, and profound alterations in consciousness. This state carries serious safety risks.</p>
      </div>
    </div>

    <div class="profile-section pharmacology">
      <h3>üß† Pharmacology & Neuroscience</h3>
      <div class="pharma-details">
        <h4>Primary Mechanism of Action</h4>
        <p>Methoxetamine is primarily an NMDA receptor antagonist, blocking glutamate activity and causing dissociative anesthesia. Unlike ketamine, MXE also acts as a dopamine and norepinephrine reuptake inhibitor, contributing to its unique euphoric and stimulating properties. This dual mechanism makes it more reinforcing and potentially more addictive than ketamine.</p>
        
        <h4>Detailed Receptor Pharmacology</h4>
        <div class="receptor-table">
          <div class="receptor-row">
            <span class="receptor-name"><strong>NMDA receptors</strong></span>
            <span class="affinity">High antagonist activity</span>
            <span class="function">Primary dissociative effects, anesthesia, ego dissolution</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Dopamine transporter (DAT)</strong></span>
            <span class="affinity">Moderate inhibition</span>
            <span class="function">Euphoria, addiction potential, mood elevation</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Norepinephrine transporter (NET)</strong></span>
            <span class="affinity">Moderate inhibition</span>
            <span class="function">Stimulation, increased energy, cardiovascular effects</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Serotonin transporter (SERT)</strong></span>
            <span class="affinity">Weak inhibition</span>
            <span class="function">Minor contribution to mood effects</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Sigma-1 receptors</strong></span>
            <span class="affinity">Agonist activity</span>
            <span class="function">Neuroprotection, possible antidepressant effects</span>
          </div>
        </div>

        <h4>Metabolism & Pharmacokinetics</h4>
        <div class="metabolism-details">
          <p><strong>Primary Pathway:</strong> Hepatic metabolism via CYP450 enzymes</p>
          <p><strong>Active metabolites:</strong> Unknown metabolic profile - limited research</p>
          <p><strong>Half-life:</strong> 3-6 hours (estimated)</p>
          <p><strong>Bioavailability:</strong> High oral bioavailability (~90%)</p>
          <p><strong>Peak plasma:</strong> 1-2 hours after oral dose</p>
          <p><strong>Duration:</strong> 4-8 hours, significantly longer than ketamine</p>
        </div>

        <h4>Neurotoxicity & Long-term Effects</h4>
        <div class="neurotoxicity-info">
          <p><strong>Bladder toxicity:</strong> Similar to ketamine - chronic use can cause cystitis</p>
          <p><strong>Cognitive effects:</strong> Potential memory impairment with heavy use</p>
          <p><strong>Addiction potential:</strong> Higher than ketamine due to dopamine activity</p>
          <p><strong>Tolerance:</strong> Develops rapidly, cross-tolerance with other dissociatives</p>
        </div>

        <h4>Unique Pharmacological Properties</h4>
        <ul>
          <li><strong>Dual mechanism:</strong> NMDA antagonism + monoamine reuptake inhibition</li>
          <li><strong>Long duration:</strong> 2-3x longer than ketamine</li>
          <li><strong>High potency:</strong> Active at much lower doses than ketamine</li>
          <li><strong>Oral activity:</strong> More orally bioavailable than ketamine</li>
          <li><strong>"Warmer" dissociation:</strong> Users report less cold/clinical feel vs. ketamine</li>
        </ul>
      </div>
    </div>

    <div class="profile-section safety">
      <h3>‚ö†Ô∏è Safety & Harm Reduction</h3>
      
      <div class="safety-grid">
        <div class="safety-item critical">
          <h4>üö® EXTREME DANGER WARNINGS</h4>
          <ul>
            <li><strong>M-hole risk:</strong> Complete loss of motor control and awareness</li>
            <li><strong>Long duration:</strong> 4-8 hours of impairment with no antidote</li>
            <li><strong>Injury risk:</strong> Cannot protect yourself while dissociated</li>
            <li><strong>Addiction potential:</strong> Higher than ketamine due to dopamine activity</li>
            <li><strong>Unknown long-term effects:</strong> Limited safety research</li>
          </ul>
        </div>
        
        <div class="safety-item precautions">
          <h4>üõ°Ô∏è Critical Precautions</h4>
          <ul>
            <li>Never use alone - have a sober, trusted sitter</li>
            <li>Start with extremely low doses (5-10mg max)</li>
            <li>Wait 2+ hours before considering redosing</li>
            <li>Remove all hazards from environment</li>
            <li>Do not combine with depressants or alcohol</li>
            <li>Avoid frequent use to prevent tolerance/addiction</li>
          </ul>
        </div>
      </div>

      <div class="contraindications">
        <h4>üö´ Absolute Contraindications</h4>
        <p><strong>Never use if you have:</strong> History of psychosis, severe depression, suicidal ideation, cardiovascular problems, or are taking antidepressants. The long duration makes MXE particularly dangerous for those with mental health conditions.</p>
      </div>
    </div>

    <div class="profile-section interactions">
      <h3>‚öóÔ∏è Drug Interactions</h3>
      
      <div class="interaction-levels">
        <div class="interaction dangerous">
          <h4>üî¥ EXTREMELY DANGEROUS</h4>
          <ul>
            <li><strong>CNS Depressants:</strong> Alcohol, benzodiazepines, opioids - respiratory depression risk</li>
            <li><strong>MAOIs:</strong> Unpredictable interactions with monoamine reuptake inhibition</li>
            <li><strong>Stimulants:</strong> Dangerous cardiovascular strain, increased risk of mania</li>
            <li><strong>Tramadol:</strong> Seizure risk, serotonin syndrome potential</li>
          </ul>
        </div>
        
        <div class="interaction risky">
          <h4>üü° High Risk</h4>
          <ul>
            <li><strong>Antidepressants:</strong> Complex interactions, increased side effects</li>
            <li><strong>Other dissociatives:</strong> Additive effects, dangerous potentiation</li>
            <li><strong>Psychedelics:</strong> Unpredictable psychological effects</li>
            <li><strong>Cannabis:</strong> Increased confusion, potential for panic</li>
          </ul>
        </div>
        
        <div class="interaction caution">
          <h4>üü† Use Extreme Caution</h4>
          <ul>
            <li><strong>Nitrous oxide:</strong> Risk of falls, oxygen deprivation</li>
            <li><strong>DXM:</strong> Both NMDA antagonists - dangerous potentiation</li>
            <li><strong>Ketamine:</strong> Cross-tolerance, additive bladder toxicity</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section legal">
      <h3>‚öñÔ∏è Legal Status</h3>
      <div class="legal-info">
        <div class="legal-jurisdictions">
          <div class="jurisdiction">
            <h4>üá∫üá∏ United States</h4>
            <p><strong>Schedule I</strong> - Illegal since 2013. No accepted medical use. Federal felony for possession or distribution.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá¨üáß United Kingdom</h4>
            <p><strong>Class B</strong> - Controlled since 2012. Up to 5 years for possession, 14 years for supply.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá™üá∫ European Union</h4>
            <p><strong>Controlled</strong> - Banned across EU member states following emergency scheduling procedures.</p>
          </div>
          <div class="jurisdiction">
            <h4>üåç International</h4>
            <p><strong>Widely banned</strong> - Most countries have scheduled MXE following safety concerns and abuse reports.</p>
          </div>
        </div>
        
        <div class="therapeutic-status">
          <h4>üè• Research Status</h4>
          <p>No legitimate medical research or therapeutic applications for methoxetamine. Its development and distribution were entirely within the "legal high" research chemical market before worldwide prohibition.</p>
        </div>
      </div>
    </div>

    <div class="profile-section history">
      <h3>üìö History & Research Chemical Era</h3>
      
      <div class="history-timeline">
        <div class="history-event">
          <span class="year">~2010</span>
          <p>First synthesized by underground chemists as "legal ketamine" alternative</p>
        </div>
        <div class="history-event">
          <span class="year">2010-2012</span>
          <p>Rapid spread through research chemical vendors and online communities</p>
        </div>
        <div class="history-event">
          <span class="year">2012</span>
          <p>First emergency scheduling actions in UK following safety concerns</p>
        </div>
        <div class="history-event">
          <span class="year">2013</span>
          <p>DEA emergency scheduling in United States as Schedule I substance</p>
        </div>
        <div class="history-event">
          <span class="year">2013-2015</span>
          <p>Worldwide scheduling wave as countries ban MXE</p>
        </div>
        <div class="history-event">
          <span class="year">2015+</span>
          <p>Virtual disappearance from legitimate research chemical market</p>
        </div>
      </div>

      <div class="cultural-impact">
        <h4>Research Chemical Context</h4>
        <p>Methoxetamine represented the peak of the "legal high" research chemical era, demonstrating how novel psychoactive substances could rapidly spread through online communities before regulatory responses. Its popularity stemmed from being marketed as "bladder-safe ketamine" with longer duration and greater potency.</p>
        
        <h4>Community Impact</h4>
        <p>MXE gained a devoted following in dissociative communities, with users praising its unique "warm" dissociation and euphoric properties. However, reports of addiction, dangerous behavior while intoxicated, and potential long-term health effects led to widespread concern and ultimate prohibition.</p>
      </div>
    </div>

    <div class="profile-section research">
      <h3>üî¨ Limited Research & Safety Concerns</h3>
      
      <div class="research-areas">
        <div class="research-item">
          <h4>Pharmacological Studies</h4>
          <p>Limited academic research focused on receptor binding profiles and basic pharmacokinetics. Most data comes from underground chemist reports and user experiences rather than controlled studies.</p>
        </div>
        
        <div class="research-item">
          <h4>Toxicology Reports</h4>
          <p>Case reports of MXE-related hospitalizations, including prolonged dissociative states, injuries while intoxicated, and potential cardiovascular effects. Limited data on chronic toxicity.</p>
        </div>
        
        <div class="research-item">
          <h4>Addiction Potential</h4>
          <p>Anecdotal reports suggest higher addiction potential than ketamine, likely due to dopamine reuptake inhibition. Some users reported rapid development of tolerance and difficulty controlling use.</p>
        </div>
        
        <div class="research-item">
          <h4>Analytical Chemistry</h4>
          <p>Research focused on detection methods for forensic and clinical purposes. Development of analytical standards following scheduling as controlled substance.</p>
        </div>
      </div>
    </div>

  </div>

  <div class="substance-resources">
    <h3>üìñ Resources & Support</h3>
    <div class="resources-grid">
      <div class="resource-item">
        <h4>Emergency Services</h4>
        <ul>
          <li><strong>Medical Emergency:</strong> Call 911/emergency services immediately</li>
          <li><strong>Poison Control:</strong> 1-800-222-1222 (US)</li>
          <li><strong>Crisis Support:</strong> National Suicide Prevention Lifeline</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Historical Information</h4>
        <ul>
          <li><a href="https://erowid.org/">Erowid</a> - Experience reports and information</li>
          <li><a href="https://psychonautwiki.org/">PsychonautWiki</a> - Research chemical data</li>
          <li><a href="https://bluelight.org/">Bluelight</a> - Historical community discussions</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Addiction Treatment</h4>
        <ul>
          <li><a href="https://www.samhsa.gov/">SAMHSA</a> - Treatment facility locator</li>
          <li><a href="https://na.org/">Narcotics Anonymous</a> - Peer support</li>
          <li><a href="https://www.smart-recovery.org/">SMART Recovery</a> - Science-based recovery</li>
        </ul>
      </div>
    </div>
  </div>

</div>
    </main>
     <div class="footer-divider"></div>
<footer class="site-footer">
  
</footer>




<footer class="site-footer">
  
  </svg>
    <img src="/assets/logo.svg" alt="My Logo" class="logo">
     <p>¬© 2025 Uwaniumnya. Highly Illegal.</p>
  </footer>

  

    <!-- Search Scripts -->
    <script src="/js/lunr.min.js"></script>
    <script src="/assets/js/search.js"></script>
    <script src="/assets/js/substance-integration.js"></script>
</body>
</html>